P38 MAP kinase inhibitors
US8299074B2 · kind B2 · utility
44Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2009 |
| Grant date | Oct 30, 2012 |
| Priority date | — |
| Expiry date | Dec 11, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compounds of formula (I):which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.